GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Debt-to-Equity

CTNM (Contineum Therapeutics) Debt-to-Equity : 0.00 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Debt-to-Equity?

Contineum Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.48 Mil. Contineum Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.11 Mil. Contineum Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $217.50 Mil. Contineum Therapeutics's debt to equity for the quarter that ended in Jun. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Contineum Therapeutics's Debt-to-Equity or its related term are showing as below:

CTNM's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Contineum Therapeutics Debt-to-Equity Historical Data

The historical data trend for Contineum Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Debt-to-Equity Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-Equity
-0.07 -0.06 -0.01

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only N/A -0.02 -0.01 -0.01 -

Competitive Comparison of Contineum Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Contineum Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Contineum Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's Debt-to-Equity falls into.



Contineum Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Contineum Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Contineum Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics  (NAS:CTNM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Contineum Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.